Conference Insider

Conference Insider

A population health model focused on health and wellness is the key to success in value-based care, according to recent research.

Researchers recently found that patients with type 2 diabetes taking metformin, a common diabetes medication, had a much lower rate of age-related macular degeneration (AMD). 

The efficacy and safety of EyePoint Pharmaceuticals Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye was supported by 24-month follow-up data presented at the Annual Meeting of the American Academy of Ophthalmology.

Currently, detecting Alzheimer disease (AD) is a challenge. However, a new, noninvasive imaging device—which examines the smallest veins in the back of the eye, including the red blood cells moving through the retina—can be used to detect signs of AD, researchers said.

According to a poster presented at the Annual Meeting of the American Academy of Ophthalmology, ocular inflammation and pain in patients following cataract surgery was effectively treated with KPI-121 1%. 

A team of researchers found that patients with health savings accounts (HSAs) who are on autoimmune drugs had a significantly higher risk for discontinuation, lower proportion of days covered, and lower monthly fill rates after implementation of a copay accumulator adjustment program (CAAP).

Despite the late timing of reports and less-than-transparent evaluation process, the Institute for Clinical and Economic Review (ICER) has potential to provide unbiased clinical and economic evaluations, according to a recent survey of payers. 

Manufacturers believe payers will begin to use the Institute for Clinical and Economic Review (ICER) assessments more frequently and that payers are also becoming more proactive by integrating ICER requirements into their evidence generation and market strategies, according to new research. 

According to a recent study presented at AMCP Nexus 2018, providing transparent cost information to prescribers resulted in a positive impact on prescribing trends, and researchers found that prescribers were willing to make retroactive conversions when there was a clear cost benefit. 

Despite their high price tag, CAR-T regimens were found to be cost-effective compared with other recently approved novel anticancer regimens, according to recent research presented at AMCP Nexus 2018.